Nuvalent (NUVL)

• Market cap: $5.06B
• 1 day: -1.37%
• 5 days: 3.94%
• 1 month: -9.36%
• 3 months: -9.73%
• 6 months: -30.16%
• Year to date: -11.66%
• 1 year: 9.57%
• 5 years: 276.85%
• 10 years: 276.85%
• Sector: Healthcare
• Industry: Biotechnology

About: Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Employees: 142

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

104% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 24

94% more repeat investments, than reductions

Existing positions increased: 95 | Existing positions reduced: 49

69% more call options, than puts

Call options by funds: $66M | Put options by funds: $39M

11% more funds holding

Funds holding: 192 [Q3] → 214 (+22) [Q4]

9% more funds holding in top 10

Funds holding in top 10: 11 [Q3] → 12 (+1) [Q4]

1.0% less ownership

Funds ownership: 108.56% [Q3] → 107.56% (-1.0%) [Q4]

23% less capital invested

Capital invested by funds: $7.15B [Q3] → $5.52B (-$1.62B) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $100 42% upside
• Avg. target: $105 49% upside
• High target: $110 56% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

UBS David Dai 8% 1-year accuracy 1 / 13 met price target	42% upside $100	Buy Upgraded	14 Mar 2025
HC Wainwright & Co. Swayampakula Ramakanth 20% 1-year accuracy 38 / 192 met price target	56% upside $110	Buy Reiterated	3 Mar 2025